RhEumatoid Arthritis MEDIcation Adherence

Recruiting now · Not applicable

Conditions studied: Rheumatoid Arthritis

In brief

Rheumatoid arthritis (RA) is a public health issue because of its frequency, its functional consequences, the risk of morbidity and mortality and the costs incurred. A collaborative multiprofessional intervention initiated during hospitalization and continued after hospital discharge (ambulatory care ) would improve medication adherence in RA and therefore the health status of patients. Main objective: To compare, 12 months after the index hospitalization or consultation, the impact of pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician) on medication adherence to disease-modifying treatments of patients with RA compared to usual care without pharmaceutical care and specific multi-professional collaboration. Medication adherence to disease-modifying treatments will be assessed by the rate of coverage of disease-modifying treatments (or Medication Possession Ratio (MPR)). METHODOLOGY: Interventional, multicenter, controlled, randomized, open label study, comparing in parallel 2 groups of patients with rheumatoid arthritis initially hospitalized in a rheumatology department (pharmaceutical care provided in multiprofessional collaboration (pharmacist-physician), initiated in the hospital and continued after hospital discharge (ambulatory care) vs traditional follow-up.

Key facts

Study ID

NCT05413759

Run by

Hospices Civils de Lyon

People needed

200

Starts

2022-06-28

Expected to finish

2027-12-28

Last updated by the study team

2025-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with diagnosed rheumatoid arthritis (RA),
• Patient, male or female, aged 18 or over,
• Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge
• Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD),
• Autonomous patient in the management of his drug treatment,
• Patient understanding and speaking French,
• Patient affiliated to the French general national health insurance or similar,
• Patient having given his free, informed and signed consent.

You may not qualify if…

• Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study,
• Patient whose regular pharmacy is currently treating another patient.
• Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator),
• Patient whose management of his drug treatment at home is carried out exclusively by a carer,
• Patient participating in another research that may interfere (investigator's judgement) with the results of the present study,
• Adult patient protected under the terms of the law (Public Health Code),
• Patient not fit to carry out the follow-up, according to the judgment of the investigator,
• Pregnant or breastfeeding women.

Where it is running

• Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot — Lyon, France (enrolling)
• Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon — Pierre-Bénite, Lyon, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.